Drug intelligence / Profile preview

verapamil + paroxetine

Development stage
Phase 4
Lead developer
GSK
Administration
Oral
01

Overview

The combination of verapamil and paroxetine is a drug therapy that has been studied for treating tinnitus. According to a randomized, double-blind, placebo-controlled clinical trial conducted between 2019 and 2023, this combination (referred to as "group VP" in the study) showed promising results in improving tinnitus severity[1][8]. ## Composition and Classification This is a combination drug therapy consisting of two distinct medications: 1. **Verapamil**: A calcium channel blocker primarily used to treat hypertension, angina, and certain cardiac arrhythmias[4]. 2. **Paroxetine**: A selective serotonin reuptake inhibitor (SSRI) antidepressant used to treat major depressive disorder, panic disorder, OCD, social phobia, generalized anxiety disorder, and other conditions[2]. ## Mechanism of Action The therapeutic effect of this combination likely stems from the complementary mechanisms of both drugs: - Verapamil works by blocking calcium channels, which affects vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced cardiac workload[4]. - Paroxetine selectively inhibits the reuptake of serotonin in the central nervous system, increasing serotonin availability at synaptic junctions[2]. Some studies suggest that calcium channel blockers like verapamil may have their own antidepressant-like effects, which could potentially enhance the effects of SSRIs like paroxetine[5]. ## Clinical Evidence In a clinical trial for tinnitus treatment, the verapamil-paroxetine combination demonstrated significant improvement in tinnitus severity. The Tinnitus Functional Index (TFI) score decreased from 54.6 ± 17.5 at baseline to 42.2 ± 16.1 at the end of the 8-week trial (P = .004)[1][8]. ## Potential Interactions There is some conflicting information regarding interactions between these medications: - One source indicates that the metabolism of paroxetine can be decreased when combined with verapamil[2], which could potentially increase paroxetine levels. - Another source states there shouldn't be any significant interactions between paroxetine and verapamil[7]. Given these potential interactions, careful monitoring would be advisable when using this combination. ## Development Status This drug combination has been studied in clinical trials for tinnitus treatment, with promising results suggesting it may be effective in improving tinnitus severity. However, researchers noted that "larger-scale trials with longer follow-up periods are warranted to validate our findings between groups"[1].

Other names
group VP
02

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on verapamil + paroxetine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on verapamil + paroxetine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call